339 results about "Retinal" patented technology

The invention discloses a nucleic acid tetrahedron DNA-quercetin compound and application of the nucleic acid tetrahedron DNA-quercetin compound in treatment of retinal neovascular diseases. In the nucleic acid tetrahedron DNA-quercetin compound disclosed by the invention, a quercetin molecule is connected to one single-stranded DNA of four single-stranded DNAs of a nucleic acid tetrahedron through an azide coupling reaction. The compound is stable in physical property, quantitatively carried quercetin molecules guarantee the stability of the treatment effect of the compound, generation of new vessels can be effectively prevented, remodeling of retina non-perfusion area vessels can be promoted, retina vascular injury can be recovered, a new strategy is provided for treatment and prevention of retina neovascular diseases, and the compound is worthy of popularization and application. Meanwhile, compared with tFNAs-QUE obtained through an existing electrostatic adsorption method, the tFNAs-QUE synthesized through the azide coupling method has a better treatment effect, pathological neovascularization is greatly reduced, and meanwhile generation of physiological blood vessels in a non-vascular region is obviously promoted.

The invention relates to the technical field of medicines, in particular to a DHEA polypeptide, a sustained-release hydrogel, a coated exosome delivery preparation and application. Assembling the DHEA on the heptapeptide to obtain a DHEA polypeptide; the amino acid sequence of the heptapeptide is FFGSSSR, and the DHEA is dehydroepiandrosterone. By introducing the FFGSSSR heptapeptide with high biocompatibility, in-vitro self-assembly encapsulation of the fat-soluble drug DHEA is realized, the fat-soluble drug DHEA is prepared into an amphiphilic preparation, and the problem that the DHEA is difficult to prepare is solved; according to the invention, the exosome is introduced, and the exosome has the effect of cooperatively regulating the retina microenvironment, so that the RIR injury is treated by multiple targets; when the exosome is obtained, the R28 cells are pretreated by utilizing BBR and an anoxic condition, so that not only is the paracrine effect of the R28 cells enhanced, but also the RIR injury treatment effect of the exosome is improved.

The invention belongs to the technical field of biological medicine, and discloses an application of CDH5 protein and / or SELL protein as a biomarker in preparation of a kit for detecting diabetic retinopathy, the biomarker comprises at least one of CDH5 protein and SELL protein; the amino acid sequence of the CDH5 protein is as shown in SEQ NO: 1, and the amino acid sequence of the SELL protein is as shown in SEQ NO: 2. The CDH5 protein and / or the SELL protein are / is used as the biomarker for detecting diabetic retinopathy, especially for detecting early diabetic retinopathy, good sensitivity and specificity can be obtained, the accuracy of a detection result is ensured, early diagnosis and early treatment are realized, sampling is convenient and non-invasive, and large-scale popularization can be realized.

The invention provides a composition which comprises two components, and the component A comprises lutein; and the component B comprises a berry fruit extract containing anthocyanin. The composition has the effects of eliminating free radicals, resisting oxidation, protecting eyes, inhibiting tear secretion reduction, relieving eyestrain and eye dryness, relieving ciliary muscle tension, repairing retina, preventing and controlling ocular axes, protecting eyesight, preventing myopia, improving eye microcirculation, improving couperose skin and the like.

The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.

The invention relates to the technical field of nutritional supplements, and discloses a pet nutritional supplement capable of improving immunity, which is prepared from the following raw materials in parts by weight: 35 to 45 parts of taurine, 5 to 8 parts of natural lutein, 10 to 30 parts of chondroitin sulfate, 10 to 20 parts of water, 20 to 30 parts of corn starch, 10 to 20 parts of semen plantaginis and 30 to 50 parts of microbial fermentation products. The 35-45 parts of taurine and the 10-30 parts of chondroitin sulfate can be selected from one or more of sardine powder, black and white fish powder, beef powder, pig powder, chicken powder and the like. According to the pet nutritional supplement capable of improving immunity and the preparation method thereof, the semen plantaginis is added into the raw materials, so that the pet kidney can be promoted to generate more urine, urethra flushing is facilitated, bacterium breeding is reduced, and urinary system infection is prevented, and the taurine is added, so that heart condition improvement, brain development promotion and retina protection are facilitated. When the pet supplement is prepared, the pet supplement is prepared by using a freeze-drying machine, so that the loss of nutrient substances is reduced.

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

The invention belongs to the technical field of marine microorganisms, and discloses an application of Propionibacterium fredenreici subsp. Schermani NHNK-616 in preparation of a product for improving macular retinae, the Propionibacterium fredenreici subsp. Schermani NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the Propionibacterium fredenreici subsp. Schermani NHNK-616 is CCTCC NO: M 20241429. The invention further discloses a preparation method of the Propionibacterium fredenreici subsp. Schermani NHNK-616. The inventor finds that the NHNK-616 has the functions of improving the oxidation resistance of the retina, increasing the retinal barrier, reducing retinal neovascularization, reducing retinal inflammation and the like, in addition, an NHNK-616 thallus biological membrane can improve the colonization capacity of nasal epithelial cells and intestinal epithelial cells, and the NHNK-616 can be used for preparing products for improving the retina macular.

The invention provides a traceable mitochondrial targeting nano system as well as a preparation method and application thereof, and belongs to the field of medicines. The traceable mitochondrial targeting nano system constructed by the invention can continuously release resveratrol and maintain the photochemical stability of resveratrol. The nano system shows efficient cellular uptake and accurate mitochondrial targeting ability, and promotes removal of mitochondrial ROS and adjustment of mitochondrial autophagy, so that vascular leakage and angiogenesis are relieved, in-vivo microvascular hyperplasia and retina degeneration are remarkably inhibited, and the curative effect is improved. The distribution of the compound in fundus can be monitored in real time through clinical ophthalmological diagnosis equipment, and the compound has a good application prospect in preparation of drugs for preventing and / or treating diabetic retinopathy.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

A trace element supplement consisting of lutein, zeaxanthin, astaxanthin, anthocyanins, and proanthocyanidins is designed to improve retinal health in children and adolescents, relieve eye strain, and slow the progression of myopia. The daily dose is 1–20 mg lutein, 0.2–4 mg zeaxanthin, 0.5–8 mg astaxanthin, 10–700 mg taurine, and 0.5–8.5 mg zinc; the nighttime dose is 1–100 mg eyebright extract, 10–300 mg chamomile extract, 1–200 mg anthocyanins, and 1–500 mg proanthocyanidins.

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

The invention provides a gene therapy drug for treating AMD (Amplified Maleic Disease). The invention provides an anti-VEGF fusion protein with a specific secretion signal peptide sequence. The anti-VEGF fusion protein can effectively express and secrete an anti-VEGF protein. The invention also provides a modified AAV vector for improving the retinal transduction efficiency of the anti-VEGF protein. The fusion protein and the modified AAV vector can be used for treating neovascular eye diseases.

The present invention discloses a method for culturing vitreoretinal organoids in vitro, comprising the following steps: (1) amplifying and culturing pluripotent stem cells to a cell confluence of 50% to 90%; (2) on day 0, digesting the stem cells with a digestion solution; adding a neurosphere culture medium for culturing; adding matrigel for culturing, and then adding a neurosphere culture medium for culturing to obtain a cell suspension; (3) adding a ROCK pathway inhibitor to the cell suspension, and culturing in the neurosphere culture medium for 3 to 5 days to obtain ectoderm neurospheres; (4) replacing the neurosphere culture medium with a vitreous culture medium I, adding TGFB1 protein, and placing the cell suspension on a shaker for 25 to 28 days; (5) replacing the vitreous culture medium I with a vitreous culture medium II, and culturing the cell suspension for 60 to 300 days to obtain vitreoretinal organoids. The vitreous organoids of the retina cultured in vitro according to the present invention can simulate the vitreous in vivo.

The invention relates to a supramolecular nano gene vector as well as a preparation method and application thereof. The supramolecular nano-carrier is prepared from beta-cyclodextrin grafted polyethyleneimine, 8-adamantane grafted polyamide-amine dendrimer, adamantane grafted polyethylene glycol and adamantane grafted polyethylene glycol modified by using a cell penetrating peptide (TAT). A CRISPR / Cas9 system is loaded through self-assembly of a nano material monomer, the prescription is screened, and the subsequent research on cells and retinal organs proves that the transfection efficiency and the RS1 protein expression quantity are good. The supramolecular nanoparticle loaded gene editing system has a good potential of treating the X-linked retina cleavage disease. Moreover, the supramolecular nanoparticle gene vector is high in biological safety, high in transfection efficiency, simple and easily available in preparation mode, and good in clinical application potential in the future.

The invention discloses a nutritional food capable of improving a night vision function and a preparation method of the nutritional food. The composition is prepared from anthocyanin-sterculia nobilis acid nano-particles, fucoxanthin-vitamin A-resveratrol nano-particles and zinc taurate. The functions of retinal rod cells can be remarkably improved, the blood microcirculation of eyes can be promoted, and the vision sensitivity and the asthenopia resistance in dark environments such as night, weak light and low visibility can be remarkably improved; the product can be prepared into capsules, tablets, electuary, oral liquid or beverage.

The invention relates to gene therapy of ocular conditions. Described herein are compositions and methods for delivering therapeutic products, such as therapeutic proteins (e.g., antibodies), therapeutic RNAs (e.g., shRNAs, siRNAs, and miRNAs), and therapeutic aptamers, to the retinal / vitreous humor of the eye of a human subject to treat ocular conditions, involving, for example, recombinant viral vectors, such as recombinant adeno-associated virus (rAAV) vectors.

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

A mixer attachment for use with a surgical hand piece includes a powder plate configured to contain a solid substance for combining with a liquid substance to form a combined substance. The mixer attachment further includes a plurality of mixing plates configured to mix the solid substance and the liquid substance in the combined substance, the plurality of mixing plates including: one or more channeled plates comprising one or more channels and one or more through holes configured to facilitate turbulent flow of the combined substance during mixing, and one or more flat plates comprising a central opening to direct flow of the combined substance between the one or more channeled plates.

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

To provide GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, fusion molecules comprising the same and pharmaceutical compositions.SOLUTION: The invention provides a GLP-1R agonistic peptide whose GLP-1R agonistic activity is about 9- to about 531-fold reduced as compared to the GLP-1R agonistic activity of native GLP-1 of a specific sequence. The invention also provides a nucleic acid molecule encoding GLP-1R agonistic peptide with reduced GLP-1R agonistic activity, a pharmaceutical composition comprising a GLP-1R agonistic peptide with reduced GLP-1R agonistic activity and combinations thereof. The pharmaceutical composition is for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.SELECTED DRAWING: None

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The present invention discloses a β-carotene-grape seed extract eye-care preparation for retinal protection, relating to functional health foods. The preparation comprises active components and food-acceptable excipients. In parts by weight, the active components include 1–4 parts lutein, 0.5 –2 parts meso-zeaxanthin, 2 – 6 parts β-carotene, 8 – 25 parts blueberry extract, 5 – 18 parts grape seed extract, 0.2–1 part L-ergothioneine, 0.5–3 parts saffron extract, and 1–5 parts phosphatidylserine. The excipients comprise a filler, disintegrant, binder, and lubricant, with a weight ratio of active components to excipients of 1:1 to 1:4. By combining these eight components at specific ratios, the invention achieves synergistic effects, protects retinal health, and reduces blue-light damage. Dual-phase microencapsulation based on solubility, together with standardized preparation steps, improves stability and utilization efficiency.

The invention provides stable ophthalmic formulations, a unit dose containing such formulations, medical kits, and methods for making and using such formulations and unit doses to treat patients suffering from a disorder mediated by an αv integrin, such as diabetic retinopathy.

The invention discloses a vitrification protective agent for retina organoid and application of the vitrification protective agent, and belongs to the technical field of organoid cryopreservation. The vitrification protective agent provided by the invention consists of 22wt% of dimethyl sulfoxide, 8wt% of ethylene glycol, 0.5 M sucrose and the balance of a culture medium. The invention also provides an application of the vitrification protective agent in retina organ cryopreservation. According to the invention, by improving the components of the protective agent, optimizing the loading and removing mode of the protective agent and selecting the cryopreservation carrier, the high-quality preservation of the retinal organs is realized. Compared with the prior art, the method has the advantages that the vitrification concentration is low, the retina organoid is fast to recover, the structural function is completely preserved, freezing and resuscitation of the retina organoid can be efficiently achieved in a high-throughput and simple-operation mode, and application requirements can be met.

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide having an excellent effect of inhibiting the generation of neovascularization in the retina, the loss of perivascular cells, and the expansion of blood vessels. The present invention can be effectively used in the prevention or treatment of retinopathy by inhibiting increase in vascular permeability, inflammation, and the occurrence of neovascularization.

The utility model provides a retina injector. The retina injector comprises a liquid injection body, an injection needle, a piston and an administration dosage control structure. The liquid injection body is provided with a hollow cavity used for containing liquid, a liquid injection opening and a material pushing opening, the liquid injection opening is communicated with the cavity and used for injecting the liquid into the cavity, and the material pushing opening is formed in one end of the cavity and communicated with the cavity. The injection needle is connected to one end of the liquid injection body. The piston is arranged in the cavity in a sliding mode through the material pushing opening. The administration dosage control structure is arranged in a mounting groove in the liquid injection body and is sealed with the mounting groove. The administration dosage control structure comprises a fixing assembly, a cover plate, a first material blocking part and a second material blocking part, the first material blocking part and the second material blocking part are both connected to the cover plate, the cover plate is movably connected to the fixing assembly, and the first material blocking part and the second material blocking part are of a linkage structure which ascends and descends in the cavity. The cover plate is operated so that the first material blocking piece or the second material blocking piece can movably stretch into the cavity to prevent the piston from sliding forwards.

The invention provides a blueberry fruit extract composition containing anthocyanin. The composition has the effects of eliminating free radicals, resisting oxidation, protecting eyes, inhibiting tear secretion reduction, relieving eyestrain and eye dryness, repairing retina, protecting eyesight, preventing and controlling myopia, improving eye blood circulation and the like.